Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Chart Trends®: Gout Report Highlights Differences Between Primary Care Physicians and Rheumatologists in the Management of Gout and Treatment Outcomes

October 14, 2010

EXTON, Pa., Oct. 14 /PRNewswire/ — BioTrends Research Group, Inc. is pleased to announce the recent release of a syndicated report focused on the management and treatment of gout in the US. ChartTrends®: Gout is an annual publication based on patient and laboratory data collected from over 1,000 gout patient charts. It provides insight into the factors that drive decisions to treat, brand selection of uric acid lowering (UAL) therapies, patient characterizations and dosing trends among primary care physicians and rheumatologists.

Based on the results from the patient record audit, primary care physicians are generally not referring their gout patients to a specialist for treatment and, instead, self-initiate both UAL therapy and gout flare medication without a rheumatology consult. However, primary care physicians face significant challenges in their training which preclude a timely, accurate diagnosis of gout. Furthermore, primary care physicians have significantly different treatment outcomes and a different mindset in preventing and treating gout flares compared to rheumatologists.

Although only one out of five physicians report that they are dissatisfied with currently available products for the treatment of moderate-to-severe gout, the majority of physicians’ patients in the record audit review had serum uric acid levels which exceed 6.0 mg/dL (a therapeutic target threshold which is associated with more frequent attacks of gout). Among new therapies in development for the treatment of gout, the most robust projections for use were associated with Ardea Biosciences’ RDEA-594 compound.

The ChartTrends®: Gout report compares what physicians self-report about disease management to what actually occurs at the patient level. It evaluates patient characteristics which impact clinical management treatment including patient demographic variables, co-morbidities, concomitant medications and lab values. Additionally, patient profiles of current UAL users and the most likely patient types identified as optimal candidates for late-stage compounds are provided in this report.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


    For more information, contact:

    BioTrends Research Group, Inc.
    Sharon Funk
    404-223-2963
    sfunk@bio-trends.com

    Decision Resources, Inc.
    Christopher Comfort
    781-993-2597
    ccomfort@dresources.com

SOURCE BioTrends Research Group, Inc.


Source: newswire